May 05, 2016
Patients with diabetic kidney disease and resistant hypertension had decreases in blood pressure while taking the hyperkalemia drug patiromer, according to a post-hoc analysis presented at a poster session at the recent National Kidney Foundation Spring Clinical Meeting in Boston, MA (April 27-May 1).
The finding stemmed from a subanalysis of 79 patients with resistant hypertension in the AMETHYST-DN trial. Published in JAMA last July, the open-label, phase II study evaluated treatment with patiromer in 304 patients with type 2 diabetes, chronic kidney disease, and hyperkalemia over 52 weeks.
In the subgroup of patients with resistant hypertension, 50 participants completed the study. By the trial’s end, participants’ systolic blood pressure decreased an average of 18.4 mmHg, and their diastolic blood pressure dropped an average of 10.1 mmHg, researchers reported.
In addition, participants with mild hyperkalemia achieved target blood potassium levels within 3 days. Participants with moderate hyperkalemia achieved target blood potassium levels within 1 week. Both groups maintained target potassium levels throughout the trial.
Among subanalysis participants, patiromer was generally well tolerated. The 2 most common adverse events were constipation and hypomagnesemia.
The blood pressure drop seen in patients with resistant hypertension “is a finding we are interesting in exploring further,” said Lance Berman, MD, chief medical officer at Relypsa, maker of patiromer.—FRMC Contributor
Data from new analyses of studies with Veltassa presented at National Kidney Foundation 2016 Spring Clinical Meetings [press release]. Relypsa: Redwood City, CA; April 28, 2016.